RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer
This study identifies RERE-AS1 as a critical regulator of tumor-immune interactions, suggesting its potential for guiding precision immunotherapy and prognostic assessment in BRCA patients.
Authors
- Hao‐Dong He
- Zhimin Li (ORCID: https://orcid.org/0000-0003-0972-952X)
- Meiling Wen
- Yuehua Li (ORCID: https://orcid.org/0000-0001-8028-248X)
- Hongbo Zhu (ORCID: https://orcid.org/0000-0002-1032-4434)
- Shaohui Jiang (ORCID: https://orcid.org/0000-0001-9901-9518)
- Weijie He (ORCID: https://orcid.org/0009-0007-6382-5738)
- Pengfei Luo (ORCID: https://orcid.org/0000-0003-0889-7660)
Institutions
- Hunan University of Science and Engineering (CN)
- First Affiliated Hospital of University of South China (CN)
- University of South China (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1007/s00262-025-04211-z
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00